FUJIFILM : Bio CDMO and Life Sciences Business Briefing
January 05, 2022 at 05:28 pm EST
Share
Bio CDMO Div. & Life Sciences Business Div.
Business Briefing
January 6, 2022
Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those
projected due to various factors.
Today's Agenda
1
2
Opening & Introduction :
Organization and Mid-term Plan for Healthcare
Takatoshi Ishikawa
FUJIFILM Corporation
Director, Senior Executive Vice President, CLSO
General Manager, Bio CDMO Division
Bio CDMO Division
Takatoshi Ishikawa
FUJIFILM Corporation
Director, Senior Executive Vice President, CLSO
General Manager, Bio CDMO Division
Life Sciences Business Division
3 Yutaka Yamaguchi
FUJIFILM Corporation
General Manager, Life Sciences Business Division
2
Healthcare / Life Sciences : New Organization (Effective on April 1, 2021)
Redefine "Healthcare" as two business groups ; "Medical Systems" and "Life Sciences".
Reorganize and strengthen Life Sciences businesses from a customer perspective, to prioritize Bio CDMO and drug development support businesses.
Become a leader within the life science industry, by offering value of end-to-end solutions as a company strongly supporting the creation of cutting-edge medicine.
Previously (～March 31, 2021)
Currently (April 1, 2021～)
Healthcare
Medical Systems Business Div.
Bio CDMO Div.
Regenerative Medicine Div. (Cell / Cell culture media)
Pharmaceutical Products Div.
Life Science Products Div. （Cosmetics / Supplements）
Healthcare
Medical Systems
Medical Systems Business Div.
* Page5-
Life Sciences
Bio CDMO Div.
CLSO
* Page28-
Life Science Business Div.
Life Sciences
(Cell/Cell culture media/Reagent)
Strategy
Headquarters
Pharmaceutical Products Div.
Consumer Healthcare Business Div.
（Cosmetics / Supplements）
3
Healthcare : Revenue Target for FY30
Healthcare will grow to ¥1.75 trillion in FY30.
¥1.75 trillion
(＄16.1B*)
Healthcare
FY30
FY21-30
Revenue
CAGR%
¥0.79 trillion (＄7.3B*)
FY21
*109 yen / USD
¥0.86
trillion
(＄7.9B*)
FY23
FY30
Medical Systems
¥1.00T
8%
(＄9.2B*)
¥0.50T
Bio CDMO
16%
(＄4.6B*)
¥0.25T
Life Sciences *
8%
(＄2.3B*)
* The total of 3 Business Divisions ;
Life Sciences, Pharmaceutical, & Consumer Healthcare.
Healthcare will represent 50% of total revenue in FY30.
50％
32％
32％
FY23
FY30
FY21
¥3.50 trillion
¥2.70 trillion
¥2.51 trillion
($32.1B*)
($23.0B*)
($24.8B*)
4
Bio CDMO Division
FUJIFILM Corporation
Director, Senior Executive Vice President, CLSO
General Manager, Bio CDMO Division
Takatoshi Ishikawa
January 6, 2022
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Fujifilm Holdings Corporation published this content on 05 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2022 22:27:05 UTC.
Fujifilm Holdings Corporation specializes in the manufacturing and marketing of printing, imaging and photography materials and equipment. Net sales break down by activity as follows:
- sale of printers and photocopiers (42.7%);
- sale of medical imaging equipment (41.4%): digital endoscopes, digital mammography devices, radiologic tables, ultrasound scan systems, etc. The group also develops pharmaceutical products development (generic drugs, health products, etc.) and design of graphic arts materials activities;
- sale of photography equipment (15.9%): digital cameras, bridges, lens, color negative films, films development materials, etc.
Net sales are distributed geographically as follows: Japan (48.7%), Americas (18.7%), Europe (10.1%) and other (22.5%).
FUJIFILM HOLDINGS CORPORATION 
